Your browser is no longer supported. Please, upgrade your browser.
Settings
ADRO Aduro BioTech, Inc. daily Stock Chart
ADRO [NASD]
Aduro BioTech, Inc.
Index- P/E- EPS (ttm)-1.21 Insider Own1.10% Shs Outstand77.18M Perf Week-10.92%
Market Cap283.25M Forward P/E- EPS next Y-0.81 Insider Trans-4.92% Shs Float45.28M Perf Month-10.05%
Income-95.40M PEG- EPS next Q-0.22 Inst Own50.30% Short Float3.93% Perf Quarter23.99%
Sales15.10M P/S18.76 EPS this Y0.30% Inst Trans-6.66% Short Ratio2.29 Perf Half Y-42.66%
Book/sh1.70 P/B2.16 EPS next Y9.00% ROA-24.60% Target Price7.00 Perf Year-58.99%
Cash/sh3.45 P/C1.06 EPS next 5Y-1.10% ROE-57.20% 52W Range2.34 - 9.85 Perf YTD39.02%
Dividend- P/FCF- EPS past 5Y-36.20% ROI-74.30% 52W High-62.74% Beta2.05
Dividend %- Quick Ratio9.30 Sales past 5Y78.70% Gross Margin- 52W Low56.84% ATR0.26
Employees152 Current Ratio9.30 Sales Q/Q-26.30% Oper. Margin- RSI (14)45.65 Volatility6.14% 6.92%
OptionableYes Debt/Eq0.00 EPS Q/Q-12.30% Profit Margin- Rel Volume0.41 Prev Close3.87
ShortableYes LT Debt/Eq0.00 EarningsMar 07 BMO Payout- Avg Volume777.50K Price3.67
Recom- SMA20-9.18% SMA504.77% SMA200-25.59% Volume316,500 Change-5.17%
Feb-22-18Initiated Cantor Fitzgerald Overweight $15
Dec-13-17Reiterated H.C. Wainwright Buy $18 → $9.50
May-01-17Initiated Rodman & Renshaw Buy $18
May-17-16Reiterated FBR Capital Outperform $30 → $22
Mar-15-16Downgrade BofA/Merrill Buy → Underperform $32 → $14
Mar-02-16Initiated FBR Capital Outperform $30
Dec-01-15Downgrade Oppenheimer Outperform → Perform
Nov-24-15Reiterated ROTH Capital Buy $74 → $68
Oct-20-15Initiated Oppenheimer Outperform $30
May-11-15Initiated Leerink Partners Outperform $48
May-11-15Initiated Canaccord Genuity Buy $43
May-11-15Initiated BofA/Merrill Buy $40
Apr-20-15Initiated ROTH Capital Buy $74
Mar-07-19 08:00AM  Aduro Biotech to Present at Two Upcoming Investor Conferences in March GlobeNewswire
Mar-01-19 10:27AM  The Meet Group (MEET) to Report Q4 Earnings: What's in Store? Zacks
09:18AM  What Should We Expect From Aduro BioTech, Inc.s (NASDAQ:ADRO) Earnings In The Years Ahead? Simply Wall St.
Feb-28-19 04:13PM  Aduro (ADRO) Q4 Earnings and Revenues Fall Shy of Estimates Zacks
09:07AM  Top Ranked Momentum Stocks to Buy for February 28th Zacks
08:00AM  Aduro Biotech Announces Upcoming Presentations at AACR Annual Meeting 2019 GlobeNewswire
Feb-27-19 04:05PM  Aduro Biotech Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
09:36AM  Top Ranked Momentum Stocks to Buy for February 27th Zacks
Feb-25-19 09:10AM  Will Aduro Biotech Continue to Surge Higher? Zacks
09:02AM  What's in Store for Universal Health (UHS) Q4 Earnings? Zacks
07:26AM  Top Ranked Momentum Stocks to Buy for February 25th Zacks
Feb-22-19 04:43PM  What's in Store for Vericel (VCEL) This Earnings Season? Zacks
Feb-21-19 08:55AM  Will Difficult Comparison Hurt Bio-Rad's (BIO) Q4 Earnings? Zacks +5.70%
08:15AM  Aduro Biotech to Present at the 8th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
08:00AM  Aduro Announces Changes to its Board of Directors GlobeNewswire
Feb-20-19 08:54AM  Will Hospice Strength Show on Amedisys' (AMED) Q4 Earnings? Zacks
07:35AM  What's in Store for Tandem Diabetes' (TNDM) Q4 Earnings? Zacks
Feb-19-19 10:07AM  What's in Store for Sangamo (SGMO) This Earnings Season? Zacks
Feb-14-19 10:45AM  The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna Zacks
07:35AM  Consolidated Research: 2019 Summary Expectations for The Trade Desk, Aduro Biotech, Walker & Dunlop, California Resources, Century Casinos, and Arsanis Fundamental Analysis, Key Performance Indications GlobeNewswire
06:49AM  Will Aduro Biotech Continue to Surge Higher? Zacks
Feb-13-19 08:36AM  5 Tiny Biotech Stocks With Superb Growth Potential Zacks
Feb-12-19 06:29PM  Aduro Initiates Dosing in Phase I Melanoma Study on ADU-S100 Zacks
Feb-11-19 04:51PM  Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards? Zacks +5.37%
09:39AM  Merrimack (MACK) Stock Up Year to Date: Is a Rebound Likely? Zacks
08:00AM  Aduro Announces First Patient Dosed in Phase 1 Study of ADU-S100 (MIW815) in Combination with YERVOY (ipilimumab) for the Treatment of Relapsed and Refractory Melanoma GlobeNewswire
Feb-08-19 10:00AM  AMAG Q4 Loss Narrower Than Expected, Revenues Lag Estimates Zacks
Feb-07-19 06:19AM  Will Aduro Biotech Continue to Surge Higher? Zacks
Feb-06-19 09:38AM  Top Ranked Momentum Stocks to Buy for February 6th Zacks
Jan-30-19 11:45PM  Why are deep-pocketed biotechs cutting hundreds of jobs? American City Business Journals +10.12%
08:00AM  Aduro Biotech Announces Strategic Reset GlobeNewswire
Jan-25-19 01:33PM  Is Aduro BioTech, Inc. (NASDAQ:ADRO) A Volatile Stock? Simply Wall St.
Jan-24-19 02:20PM  Athersys' (ATHX) MultiStem Cell Therapy Succeeds in Study Zacks
10:46AM  Vertex Terminates COO Ian Smith on Code of Conduct Violation Zacks
10:08AM  Amicus (FOLD) Boasts Strong Pipeline Amid Stiff Competition Zacks
Jan-22-19 09:31AM  Vertex's Orkambi Wins EU Nod to Treat Cystic Fibrosis in Kids Zacks
Jan-21-19 09:09AM  Aduro Biotech (ADRO) Upgraded to Strong Buy: What Does It Mean for the Stock? Zacks
Jan-03-19 08:00AM  Aduro Biotech to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire +7.69%
Dec-24-18 09:53AM  Health Care Digest: 'Killing off' the JPM Week golden goose, a $75 million complement and more American City Business Journals
Dec-20-18 11:18AM  What You Must Know About Aduro BioTech, Inc.s (NASDAQ:ADRO) Financial Strength Simply Wall St.
10:13AM  The Zacks Analyst Blog Highlights: Amgen, Aduro, Vertex, Evofem and Incyte Zacks
06:50AM  Today's Research Reports on Trending Tickers: Aduro BioTech and Adial Pharmaceuticals ACCESSWIRE
Dec-19-18 12:30PM  These 4 Pharma Stocks Are Heating Up ACCESSWIRE +19.84%
10:23AM  Aduro Stock Surges on STING Activator Deal With Eli Lilly Zacks
09:17AM  Biotech Stock Roundup: Pipeline Updates From VRTX & AMGN, ADRO Teams Up With LLY Zacks
07:00AM  Today's Research Reports on Trending Tickers: Nektar Therapeutics and Aduro BioTech ACCESSWIRE
Dec-18-18 04:15PM  Lilly and Aduro Biotech Announce Research Collaboration and License Agreement to Develop Novel Immunotherapies PR Newswire -6.08%
Dec-12-18 08:00AM  Aduro Biotech Data Published in Cell Reports Highlights the Significant Role of the Magnitude of Intratumoral STING Activation by ADU-S100 in Anti-Tumor Immunity GlobeNewswire
Dec-05-18 06:08AM  Aduro Biotech Enters Oversold Territory Zacks
Dec-03-18 08:00AM  Aduro Biotech and Dana-Farber Cancer Institute Present Preclinical Data Supporting Anti-APRIL Antibody BION-1301 for the Treatment of Multiple Myeloma at the 60th American Society of Hematology Annual Meeting and Exposition GlobeNewswire
Nov-09-18 07:30AM  Aduro Biotech Presents Preliminary Results from Ongoing Phase 1 Trials of STING agonist ADU-S100 (MIW815) in Patients with Advanced Solid Tumors or Lymphomas GlobeNewswire -13.78%
Nov-06-18 04:16PM  Aduro to Host and Webcast an Investor Event to Review Data Presented at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting GlobeNewswire -6.47%
Nov-02-18 07:45AM  New Research: Key Drivers of Growth for Shutterfly, Aegion, Columbia Property Trust, Aduro Biotech, IQVIA, and Intelsat S.A Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Oct-31-18 11:17AM  Aduro (ADRO) Q3 Loss Narrower Than Expected, Revenues Lag Zacks
Oct-30-18 07:00PM  Aduro Biotech (ADRO) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:01PM  Aduro Biotech Reports Third Quarter 2018 Financial Results GlobeNewswire
Oct-26-18 04:01PM  Aduro Presents Preclinical Data for Anti-APRIL Antibody BION-1301 for the Treatment of IgA Nephropathy at ASN Kidney Week 2018 GlobeNewswire +7.49%
Oct-23-18 10:32AM  Aduro Biotech (ADRO) Q3 Earnings Preview: What's in the Cards? Zacks
Oct-22-18 05:53PM  Why Aduro Biotech Crashed 29.5% Today Motley Fool -29.46%
Oct-01-18 04:05PM  Aduro Biotech Announces Four Abstracts Accepted for Presentation at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting GlobeNewswire
Sep-25-18 04:45PM  Aduro Biotech to Present at Two Investor Conferences in October GlobeNewswire
Sep-19-18 09:00AM  Aduro Biotech Announces the Departure of Natalie R. Sacks, M.D. GlobeNewswire -5.19%
08:45AM  Implied Volatility Surging for Aduro BioTech (ADRO) Stock Options Zacks
Sep-18-18 12:36PM  Are Insiders Cautious About Aduro BioTech Inc (NASDAQ:ADRO) Shares? Simply Wall St. +8.87%
Sep-04-18 04:06PM  Aduro Biotech and Dana-Farber Cancer Institute Publish Data Highlighting Immunosuppressive Impact of APRIL in Multiple Myeloma in Leukemia GlobeNewswire
04:01PM  Aduro Biotech Presents Preclinical Data for BION-1301, a First-in-Class Antibody Targeting Human APRIL, at the 2018 European Congress of Immunology GlobeNewswire
Aug-31-18 10:18AM  Aduro Biotech (ADRO) Up 17.4% Since Last Earnings Report: Can It Continue? Zacks +9.63%
Aug-29-18 04:01PM  Aduro Biotech to Present at the 20th Annual H.C. Wainwright Global Investment Conference GlobeNewswire
07:50AM  Recent Analysis Shows Clearwater Paper, Aduro Biotech, Comtech Telecommunications, Ferroglobe, Badger Meter, and Donnelley Financial Solutions Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Aug-01-18 06:55PM  Aduro Biotech (ADRO) Reports Q2 Loss, Lags Revenue Estimates Zacks -7.69%
05:48PM  Aduro Biotech: 2Q Earnings Snapshot Associated Press
04:01PM  Aduro Biotech Reports Second Quarter 2018 Financial Results GlobeNewswire
Jul-26-18 07:20AM  Free Technical Research on Advaxis and Three More Biotech Equities ACCESSWIRE
Jun-29-18 07:45AM  Report: Developing Opportunities within Newfield Exploration, Heritage Insurance, AptarGroup, Alder BioPharmaceuticals, TrueCar, and Aduro Biotech Future Expectations, Projections Moving into 2018 GlobeNewswire
Jun-07-18 04:01PM  Aduro Biotech Announces Initiation of Phase 1b Clinical Trial in Non-Small Cell Lung Cancer under Janssen Strategic Partnership for ADU-214 in Combination with Nivolumab GlobeNewswire
07:45AM  Complimentary Technical Snapshots on Adverum Biotechnologies and Three More Biotech Stocks ACCESSWIRE
Jun-01-18 10:48AM  Why is Aduro (ADRO) Up 18.6% Since Its Last Earnings Report? Zacks
May-17-18 08:00AM  Detailed Research: Economic Perspectives on Churchill Downs, Nordic American Tankers, News Corporation, Aduro Biotech, MannKind, and Crane What Drives Growth in Today's Competitive Landscape GlobeNewswire
May-10-18 04:01PM  Aduro Biotech to Present at the Bank of America Merrill Lynch 2018 Health Care Conference GlobeNewswire
May-04-18 11:56AM  Aduro (ADRO) Q1 Loss Narrower Than Expected, Revenues Beat Zacks
May-02-18 05:59PM  Aduro Biotech: 1Q Earnings Snapshot Associated Press
04:01PM  Aduro Biotech Reports First Quarter 2018 Financial Results GlobeNewswire
Apr-26-18 08:00AM  Aduro Biotech Presents Early Observations From its Personalized Neoantigen-based pLADD Therapy Clinical Study at European Neoantigen Summit GlobeNewswire
Apr-17-18 04:01PM  Aduro Biotech Highlights Preclinical Data for Three Programs Reported at the American Association for Cancer Research Annual Meeting GlobeNewswire
Apr-02-18 04:01PM  Aduro Biotech to Present at the H.C. Wainwright Annual Global Life Sciences Conference GlobeNewswire
Mar-28-18 10:39AM  Chinese investors jump into $70 million round for early-stage S.F. cancer-fighting company American City Business Journals
Mar-22-18 07:48AM  Global funds manager scores big gains with stock picks that may surprise you MarketWatch
Mar-14-18 04:31PM  Aduro Biotech Announces Upcoming Data Presentations at the 2018 American Association for Cancer Research Annual Meeting GlobeNewswire +5.11%
04:01PM  Aduro Biotech to Present at the 28th Annual Oppenheimer Healthcare Conference GlobeNewswire
Mar-07-18 04:01PM  Aduro Biotech to Present at the 38th Annual Cowen Healthcare Conference GlobeNewswire +8.03%
Mar-05-18 04:05PM  Aduro Announces Milestone Achieved under Merck Collaboration for Initiation of Anti-CD27 Phase I Trial in Advanced Solid Tumors GlobeNewswire
04:01PM  Aduro Biotech Appoints Hans van Eenennaam Executive Vice President Antibody Research and Site Head, Aduro Biotech Europe GlobeNewswire
Mar-01-18 04:51PM  Aduro Biotech reports 4Q loss Associated Press
04:01PM  Aduro Biotech Announces Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
07:35AM  Analysis: Positioning to Benefit within Penumbra, Qualys, OraSure Technologies, Air Lease, Aduro Biotech, and Progenics Pharmaceuticals Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Feb-08-18 04:31PM  Aduro Biotech to Present at the Leerink Partners 7th Annual Global Healthcare Conference GlobeNewswire
Jan-22-18 11:47PM  SE Asia Stocks-Most rise; Indonesia hits fresh high Reuters
Jan-05-18 08:00AM  Aduro Biotech Announces Management Changes GlobeNewswire
07:30AM  Report: Developing Opportunities within Aduro Biotech, Progenics Pharmaceuticals, Gevo, OSI, Senseonics, and Donnelley Financial Solutions Future Expectations, Projections Moving into 2018 GlobeNewswire
Jan-04-18 04:01PM  Aduro Biotech to Present at the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire +5.41%
Aduro BioTech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer. Its products pipeline also comprises BION-1301, a B-select monoclonal antibody novel therapy for multiple myeloma; A PRoliferation-Inducing Ligand for the treatment of multiple myeloma, chronic lymphocytic leukemia, and colorectal carcinoma; CD27, a co-stimulatory receptor for the treatment of cancer; and CTLA-4 for the treatment of advanced melanoma and other cancers. The company's pLADD program is based on proprietary attenuated strains of Listeria that have been engineered to express tumor neo antigens that are specific to an individual patient's tumor. It has collaboration agreements with Novartis Pharmaceuticals Corporation, Janssen Biotech, Inc, and Merck. The company was formerly known as Oncologic, Inc. and changed its name to Aduro BioTech, Inc. in June 2008. Aduro BioTech, Inc. was founded in 2000 and is based in Berkeley, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
van Elsas AndreaChief Scientific OfficerMar 19Sale3.966,08124,107239,557Mar 21 05:35 PM
van Elsas AndreaChief Scientific OfficerFeb 26Sale4.256,84429,120245,638Feb 27 07:07 PM
van Elsas AndreaChief Scientific OfficerDec 28Sale2.571,9074,901252,482Dec 31 04:02 PM
Lew JenniferChief Financial OfficerDec 12Sale2.931,0353,035135,155Dec 14 04:19 PM
Templeman BlaineChief Legal OfficerDec 12Sale2.931,2413,639129,878Dec 14 04:18 PM
ISAACS STEPHEN TPresident and CEODec 12Sale2.935,82917,091327,024Dec 14 04:17 PM
van Elsas AndreaChief Scientific OfficerDec 12Sale2.932,1716,365254,389Dec 14 04:15 PM
Templeman BlaineChief Legal OfficerNov 20Sale2.918432,453131,119Nov 20 07:58 PM
van Elsas AndreaChief Scientific OfficerSep 24Sale5.837,72645,022256,560Sep 25 08:11 PM
Templeman BlaineChief Legal OfficerSep 24Sale5.8110,26259,613131,119Sep 25 08:10 PM
Templeman BlaineExecutive VP, General CounselSep 13Sale6.506,05639,360141,381Sep 14 07:29 PM
van Elsas AndreaChief Scientific OfficerSep 13Sale6.509,75463,394264,286Sep 14 07:28 PM
Lew JenniferChief Financial OfficerSep 13Sale6.505,62336,546136,190Sep 14 07:27 PM
Sacks NatalieChief Medical OfficerSep 13Sale6.503,02819,680173,720Sep 14 07:25 PM
ISAACS STEPHEN TPresident and CEOSep 13Sale6.5024,143156,913332,853Sep 14 07:24 PM
ISAACS STEPHEN TPresident and CEOSep 06Option Exercise1.0046,98746,987252,733Sep 06 07:42 PM
ISAACS STEPHEN TPresident and CEOSep 06Sale7.9246,987372,024205,746Sep 06 07:42 PM
ISAACS STEPHEN TPresident and CEOSep 05Option Exercise1.0015,58515,585221,331Sep 06 07:42 PM
ISAACS STEPHEN TPresident and CEOSep 05Sale7.9015,585123,134205,746Sep 06 07:42 PM
Sacks NatalieChief Medical OfficerSep 04Sale7.134,50432,09989,548Sep 06 07:40 PM
van Elsas AndreaChief Scientific OfficerJul 17Sale6.9610,45472,803206,215Jul 19 07:39 PM
ISAACS STEPHEN TPresident and CEOJun 01Option Exercise1.0040,00040,000245,746Jun 05 08:58 PM
ISAACS STEPHEN TPresident and CEOJun 01Sale8.6840,000347,004205,746Jun 05 08:58 PM
Templeman BlaineChief Legal OfficerMay 17Sale8.152,00016,30069,937May 21 06:25 PM
ISAACS STEPHEN TPresident and CEOMay 09Option Exercise0.9740,00038,976245,746May 11 05:00 PM
ISAACS STEPHEN TPresident and CEOMay 09Sale8.0140,000320,348205,746May 11 05:00 PM
ISAACS STEPHEN TPresident and CEOApr 02Option Exercise0.8240,00032,800245,746Apr 04 06:26 PM
ISAACS STEPHEN TPresident and CEOApr 02Sale8.9140,000356,400205,746Apr 04 06:26 PM